Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics said that the first gastric cancer patient had been dosed in its phase II clinical study to evaluate ABSK061 and ABSK043 for solid tumors.
A Phase II clinical trial is underway to evaluate the safety and effectiveness of ABSK061 and ABSK043 with or without chemotherapy in patients with metastatic or unresectable advanced solid tumors with FGFR2/3 alterations, according to a Friday disclosure with the Hong Kong Exchange.
ABSK061 is a clinically advanced, orally bioavailable, potent, and selective inhibitor of FGFR2 and FGFR3, while ABSK043 is an orally available, potent inhibitor targeting PD-L1.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。